Your session is about to expire
← Back to Search
Family Communication Intervention for Dilated Cardiomyopathy
N/A
Waitlist Available
Led By Ray Hershberger, MD
Research Sponsored by Ray Hershberger
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Meeting criteria for dilated cardiomyopathy (DCM) with specific left ventricular ejection fraction and left ventricular enlargement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2.5 years
Awards & highlights
Study Summary
This trial is testing whether or not a disease has a genetic basis and whether or not a family communication intervention can help improve uptake and impact of clinical screening for family members.
Who is the study for?
This study is for individuals of any age with dilated cardiomyopathy (DCM), a heart condition where the heart's ability to pump blood is decreased. Participants must not have other detectable causes for DCM, severe untreated hypertension, or active diseases that could cause DCM. They should be able to give consent and communicate in English or Spanish at certain sites.Check my eligibility
What is being tested?
The trial aims to understand if genetics play a major role in DCM and assesses the effectiveness of using a 'Family Heart Talk Booklet' to improve clinical screening among family members.See study design
What are the potential side effects?
Since this intervention involves educational material rather than medication, there are no direct medical side effects expected from participating in this trial.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My heart is enlarged and doesn't pump well.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2.5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2.5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Family clinical screening completed within 12 months from proband enrollment.
Living first-degree relative adheres to cardiovascular surveillance recommendations after return of genetic results.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Communication ToolExperimental Treatment1 Intervention
Group II: No Communication ToolActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Ray HershbergerLead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,833 Previous Clinical Trials
47,299,996 Total Patients Enrolled
National Human Genome Research Institute (NHGRI)NIH
263 Previous Clinical Trials
277,632 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
In what regions are the participants of this trial being recruited?
"Participants for this clinical trial can be found at South Miami Heart Center in Florida, University of Alabama at Birmingham, and UCLA Medical Center. Additionally, 27 other enrolment sites are available throughout the United States."
Answered by AI
Is this research endeavor still enrolling participants?
"This clinical trial is no longer accepting patients, as the last update was on September 19th 2022. Nevertheless, there are still 168 other active studies that require participants at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger